Payment overview · 2025
General Payments
$188.80
11 reported records · 8 companies
Healthcare provider profile · identity verified
Mark David Haugen, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WALLA WALLA, WA · NPI 1700890597
Verified facts
What the public records show
CMS Open Payments records show Mark David Haugen, M.D. received $188.80 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.99 | 25.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.70 | 18.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.34 | 11.8% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $22.17 | 11.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.99 | 10.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.92 | 8.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $14.06 | 7.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.63 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $188.80 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
119 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 569 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 343 | 83 |
| Gabapentin | Gabapentin | 326 | 67 |
| Omeprazole | Omeprazole | 316 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 308 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 296 | 69 |
| Lisinopril | Lisinopril | 278 | 71 |
| Losartan Potassium | Losartan Potassium | 260 | 51 |
| Furosemide | Furosemide | 243 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 234 | 64 |
| Metformin Hcl | Metformin Hcl | 211 | 44 |
| Potassium Chloride | Potassium Chloride | 162 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 159 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 35 |
| Simvastatin | Simvastatin | 148 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 146 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 140 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 121 | 24 |
| Eliquis | Apixaban | 119 | 21 |
| Sertraline Hcl | Sertraline Hcl | 112 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 96 | 21 |
| Allopurinol | Allopurinol | 92 | 23 |
| Trazodone Hcl | Trazodone Hcl | 86 | 23 |
| Finasteride | Finasteride | 83 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | 16 |
| Lorazepam | Lorazepam | 79 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 79 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 78 | 13 |
| Donepezil Hcl | Donepezil Hcl | 75 | 11 |
| Mirtazapine | Mirtazapine | 75 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 75 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 13 |
| Memantine Hcl | Memantine Hcl | 68 | suppressed |
| Celecoxib | Celecoxib | 63 | 17 |
| Jardiance | Empagliflozin | 62 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 62 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 14 |
| Famotidine | Famotidine | 60 | 11 |
| Glimepiride | Glimepiride | 59 | 11 |
| Synthroid | Levothyroxine Sodium | 59 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | suppressed |
| Clonazepam | Clonazepam | 55 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 21 |
| Baclofen | Baclofen | 53 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 53 | 15 |
| Buspirone Hcl | Buspirone Hcl | 51 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | suppressed |
| Bupropion Xl | Bupropion Hcl | 50 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 50 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 13 |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Pregabalin | Pregabalin | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 30 |
| Atenolol | Atenolol | 40 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Alprazolam | Alprazolam | 39 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 11 |
| Ondansetron Odt | Ondansetron | 39 | 13 |
| Prednisone | Prednisone | 39 | 22 |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Lovastatin | Lovastatin | 38 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | 12 |
| Carvedilol | Carvedilol | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | 11 |
| Ozempic | Semaglutide | 34 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 32 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Fentanyl | Fentanyl | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 14 |
| Nystatin | Nystatin | 23 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | 11 |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Arnuity Ellipta | Fluticasone Furoate | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 11 |
| Topiramate | Topiramate | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Xtampza Er | Oxycodone Myristate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Progesterone | Progesterone, Micronized | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Cartia Xt | Diltiazem Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Tri-Linyah | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $188.80 · 11 records | ABBVIE INC. | AJOVY, CREON, INJECTAFER, Kerendia, Korlym, NURTEC ODT, QULIPTA, REXULTI, UBRELVY, VOQUEZNA, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error